Business
New Niagen® Nicotinamide Riboside (NR) Study Deepens Understanding of NAD Decline and Hearing Loss in Animal Model
Preclinical study demonstrates the effects of short-term nicotinamide riboside (NR) supplementation in preventing hearing loss in animal models LOS ANGELES,
About this update from Niagen Bioscience, Inc.
[{"type":"text","content":"Preclinical study demonstrates the effects of short-term nicotinamide riboside (NR) supplementation in preventing hearing loss in animal models\nLOS ANGELES, Feb. 27, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science, announced today the publication of a preclinical study in the journal Aging and Mechanisms of Disease, part of Nature Partner Journals. Conducted by the National Institute on Aging and the National Institute on Deafness and Other Communication Disorders, components of the National Institutes of Health, and the University of Copenhagen, the study demonstrated a reduction of hearing loss from Niagen® supplementation in mice.\n “These findings are potentially meaningful for those with Cockayne syndrome as well as the broader aging population who experience hearing loss,” commented Dr. Vilhelm A. Bohr, Senior Investigator, NIH National Institute on Aging, and study principal investigator. “The next step is to move this animal model research into a human trial.” Further investigation into this research is important given that approximately one in three people between the ages of 65 and 74 experiences hearing loss and nearly half of those older than 75 have difficulty hearing. The hearing loss experienced by Cockayne syndrome patients is similar to the sensorineural age-related hearing loss (ARHL) commonly found in older adults. Currently, there is a great need for additional interventions given the only remedies include assistive devices such as hearing aids, and no preventative measures are available. As documented in previously published preclinical research, nicotinamide adenine dinucleotide (NAD) depletion plays an important role in the cause of ARHL, and these latest preclinical trial results suggest NR, a proven NAD booster, may exert a dose-dependent reduction in hearing loss by aiding auditory interpretation and neurotransmission of sounds to the brain. These results reinforce findings from earlier preclinicals which suggested NR may help in delaying or reducing age-related hearing loss (ARHL), though further studies are required to confirm these findings in humans. ChromaDex supplied its novel ingredient, Niagen® (nicotinamide riboside), as research material for the independent study. “We apprec...